Quantcast
Last updated on April 18, 2014 at 10:04 EDT

Kiadis Pharma Participates in Haploidentical Transplantation 2013 Forum

December 5, 2013

AMSTERDAM, December 5, 2013 /PRNewswire/ –

~ Prior to the American Society of Hematology Annual Meeting ~

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments
for blood cancers, today announces that its lead product inventor, Denis-Claude Roy, MD,
Professor of Medicine at the University of Montreal, is providing the following
presentation: “Donor lymphocytes selectively photodepleted of alloreactive T cells can
fight infections without causing GVHD” at the Haploidentical Transplantation 2013 forum in
Metairie/New Orleans on December 5, 2013 prior to the annual meeting of the American
Society of Hematology (ASH).

During the session, Professor Denis-Claude Roy will provide an update on Kiadis
Pharma’s currently ongoing international multi-center Phase II study including patients
with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic
syndrome (MDS). Professor Roy will also discuss data announced by Kiadis Pharma in
September 2013 which, following the completion of its Phase I/II clinical study with
ATIR(TM), demonstrated 67% survival after five years with no Transplant Related Mortality
in the patients who received an efficacious dose of ATIR(TM). ATIR(TM) is a T-cell
immunotherapy designed to enable stem cell transplantations from partially mismatched
(haploidentical) family donors for patients who do not have a standard of care stem cell
donor available. The results demonstrated proof of concept and showed that ATIR(TM)
infusion after a T-cell depleted haploidentical hematopoietic stem cell transplantation
provides immune protection shortly after the transplantation and improves long-term
outcome in high-risk patients with very poor prognosis.

The international multi-center Phase II study including patients with AML, ALL and
MDS, to corroborate and extend the safety and efficacy results from the Phase I/II study,
is progressing according to plan with topline data expected in the first half of 2014.

ATIR(TM) has been granted Orphan Drug Designation both in the EU and the USA.
Together, both regions represent a combined primary market potential of more than EUR 1
billion per year.

About ATIR(TM)

ATIR(TM) is a T-cell based medicinal product enabling stem cell transplantations using
partially mismatched (haploidentical) family members as donors for patients suffering from
blood cancer who do not have a standard of care stem cell donor available. A hematopoietic
stem cell transplantation (HSCT) is the only potentially curative option for many patients
but a matching donor is available for only half of the patients in need. ATIR(TM) thus has
the potential to address this unmet need and to make a HSCT available for all patients
worldwide.

Those T-cells in a haploidentical graft which would cause Graft-versus-Host-Disease
(GvHD) are selectively eliminated using proprietary technology to produce ATIR(TM).
ATIR(TM) is administered as an adjunctive treatment after a T-cell depleted haploidentical
HSCT facilitating early immune reconstitution without causing life-threatening (acute)
GvHD.

In a Phase I/II study in which high-risk leukemia patients with very poor prognosis
were treated with escalating doses of ATIR(TM) after a haploidentical HSCT, long- term
safety, efficacy and proof of concept were confirmed in terms of absence of Grade III/IV
(life-threatening) acute GvHD, reduced rates of infection, reduced Transplant Related
Mortality and high Overall Survival. Positive follow-up results from this study
demonstrating 67% survival after five years and no Transplant Related Mortality in the
nine patients who received an efficacious dose of ATIR(TM) were recently reported.

About Kiadis Pharma

Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company focused on
the development of innovative and potentially life-saving therapies for patients with late
stage blood cancers and related disorders, an area of significant unmet medical need.

Kiadis Pharma’s lead product is ATIR(TM), a cell based product designed to enable stem
cell transplantations from partially mismatched (haploidentical) family donors. Kiadis
Pharma is collaborating with internationally renowned centers in Europe and North America
for the successful development and manufacturing of ATIR(TM). Kiadis Pharma recently
obtained a GMP manufacturing license and GMP certificate for its Quality Control
laboratory

Kiadis Pharma is supported by a strong group of leading international investors
including LSP, Alta Partners, DFJ Esprit, Quest for Growth, MedSciences Capital and NOM.
Kiadis Pharma is based in Amsterdam, The Netherlands. Further information can be found at:

http://www.kiadis.com

        Company Contact:
        Manfred Ruediger, CEO
        Kiadis Pharma
        Entrada 231-234
        1096 EG Amsterdam
        The Netherlands
        Tel. +31-20-314-02-50
        communication@kiadis.com

        Media and Investor Contact:
        Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
        Consilium Strategic Communications
        Tel: +44(0)207-920-2354
        kiadis@consilium-comms.com

SOURCE Kiadis Pharma


Source: PR Newswire